amsacrine has been researched along with verapamil in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cattan, AR; Davies, SM; Hall, AG; Harris, AL; Hickson, ID; Hoban, PR; Robson, CN | 1 |
| de Jong, S; de Vries, EG; Mulder, NH; Zijlstra, JG | 1 |
| Darkin, S; Ralph, RK | 1 |
| Baguley, BC; Ferguson, LR | 1 |
| Andersson, BS; Beran, M; Mavligit, GM; McCredie, KB; Stuckey, SE | 1 |
| Baguley, BC; Davey, MW; Davey, RA; Hargrave, RM; Harvie, RM; Su, GM | 1 |
12 other study(ies) available for amsacrine and verapamil
| Article | Year |
|---|---|
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C.
Topics: Amsacrine; Animals; CHO Cells; Colony-Forming Units Assay; Cricetinae; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Gene Expression; Glutathione Transferase; Humans; Hybrid Cells; Infant, Newborn; Mitomycin; Verapamil | 1992 |
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Cycle; Cell Division; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Verapamil | 1990 |
Potentiation of 4'-(9-acridinylamino)methanesulphon-m-anisidine) action by verapamil.
Topics: Aminoacridines; Amsacrine; Animals; Cell Line; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Mast-Cell Sarcoma; Mice; Structure-Activity Relationship; Verapamil | 1986 |
Verapamil modulates mutagenicity of antitumour acridines in bacteria and yeast.
Topics: Acridines; Amsacrine; Animals; Cell Line; Doxorubicin; Drug Resistance; Leukemia, Experimental; Mice; Mutagenicity Tests; Saccharomyces cerevisiae; Salmonella typhimurium; Verapamil | 1986 |
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil.
Topics: Acute Disease; Adult; Aged; Amsacrine; Cells, Cultured; Doxorubicin; Drug Resistance; Drug Synergism; Female; Humans; Leukemia; Male; Middle Aged; Verapamil | 1987 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Line; Cell Survival; Daunorubicin; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin; Leukemia; Paclitaxel; Phenotype; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |